Deutsch English Français

Contact

EP1620117

European procedure

Quick help

Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...

News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...

Extract from the Register of European Patents

EP About this file: EP1620117

EP1620117 - IMPROVED ANTITUMORAL TREATMENTS [Right-click to bookmark this link]
Status	The application is deemed to be withdrawn Status updated on 23.12.2016 Database last updated on 02.08.2024
Most recent event Tooltip	23.12.2016	Application deemed to be withdrawn	published on 25.01.2017 [2017/04]
Applicant(s)	For all designated states PHARMA MAR, S.A. Calle de la Calera 3, Poligono Industrial de Tres Cantos 28760 Tres Cantos Madrid / ES
	[2006/05]
Inventor(s)	01 / BARNEJEE, Debabrata he Cancer Inst. of New Jersey R. W. Johnson Med. School 195 Little Albany Street New Brunswick NJ 08903 / US
	02 / BERTINO, J. R. c/o The Cancer Inst. of New Jersey R.W. Johnson Med. School 195 Little Albany Street New Brunswick NJ 08903 / US
	03 / FAIRCLOTH, Glynn, Thomas c/o PharmaMar USA, Inc. 320 Putnam Avenue Cambridge MA 02139-4616 / US
	04 / GURAY, Saydam The Cancer Institute of New Jersey R.W. Johnson Med. School 195 Little Albany Street New Brunswick NJ 08903 / US
	05 / JIMENO, Jose Pharma Mar S.A. Poligono Industrial La Mina Avda. de los Reyes, 1 Colmenar Viejo 28770 Madrid / ES
	[2006/05]
Representative(s)	Fleck, Barbara Marks & Clerk LLP 62-68 Hills Road Cambridge CB2 1LA / GB
	[N/P]
Former [2010/23]	Fleck, Barbara Marks & Clerk LLP 62-68 Hills Road Cambridge CB2 1LA / GB
Former [2006/05]	Ruffles, Graham Keith Marks & Clerk 66-68 Hills Road Cambridge CB2 1LA / GB
Application number, filing date	04720399.7	12.03.2004
	[2006/05]
	WO2004US07606
Priority number, date	US20030454125P	12.03.2003 Original published format: US 454125 P
	[2006/05]
Filing language	EN
Procedural language	EN
Publication	Type:	A2 Application without search report
	No.:	WO2004080421
	Date:	23.09.2004
	Language:	EN
	[2004/39]
	Type:	A2 Application without search report
	No.:	EP1620117
	Date:	01.02.2006
	Language:	EN
	The application published by WIPO in one of the EPO official languages on 23.09.2004 takes the place of the publication of the European patent application.
	[2006/05]
Search report(s)	International search report - published on:	US	09.06.2005
	(Supplementary) European search report - dispatched on:	EP	29.06.2009
Classification	IPC:	A61K38/15, A61P35/00	[2009/31]
	CPC:	A61K38/15 (EP,KR,US); A61P19/08 (EP); A61P35/00 (EP); A61P35/02 (EP); A61P35/04 (EP)
	C-Set:	A61K38/15, A61K2300/00 (EP,US)
	Former IPC [2006/05]	A61K38/00
Designated contracting states	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LI, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR [2006/05]
Extension states	AL	Not yet paid
	LT	Not yet paid
	LV	Not yet paid
	MK	Not yet paid
Title	German:	VERBESSERTE ANTITUMORALE BEHANDLUNGEN	[2006/05]
	English:	IMPROVED ANTITUMORAL TREATMENTS	[2006/05]
	French:	TRAITEMENT ANTITUMORAUX AMELIORES	[2006/05]
Entry into regional phase	02.08.2005	National basic fee paid
	02.08.2005	Search fee paid
	02.08.2005	Designation fee(s) paid
	02.08.2005	Examination fee paid
Examination procedure	02.08.2005	Examination requested [2006/05]
	29.10.2009	Despatch of a communication from the examining division (Time limit: M04)
	28.05.2010	Despatch of a communication from the examining division (Time limit: M06)
	06.12.2010	Reply to a communication from the examining division
	15.03.2016	Cancellation of oral proceeding that was planned for 17.06.2016
	24.03.2016	Communication of intention to grant the patent
	17.06.2016	Date of oral proceedings (cancelled)
	04.08.2016	Application deemed to be withdrawn, date of legal effect [2017/04]
	09.09.2016	Despatch of communication that the application is deemed to be withdrawn, reason: fee for grant / fee for printing not paid in time [2017/04]
Divisional application(s)	The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is 29.10.2009
Fees paid	Renewal fee
	09.03.2006	Renewal fee patent year 03
	14.03.2007	Renewal fee patent year 04
	14.03.2008	Renewal fee patent year 05
	13.03.2009	Renewal fee patent year 06
	25.03.2010	Renewal fee patent year 07
	28.03.2011	Renewal fee patent year 08
	26.03.2012	Renewal fee patent year 09
	27.03.2013	Renewal fee patent year 10
	27.03.2014	Renewal fee patent year 11
	27.03.2015	Renewal fee patent year 12
	31.03.2016	Renewal fee patent year 13
Opt-out from the exclusive Tooltip competence of the Unified Patent Court	See the Register of the Unified Patent Court for opt-out data
	Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:	Search	[X]WO0135974 (PHARMA MAR SA [ES], et al) [X] 1-4,6-8,10,11,13,14,16,17 * claims 1,4 *;
		[X]WO02058688 (MEYER DOMINIK [CH]) [X] 13,14 * claims 1,22,26,27 *;
		[PX]WO03033013 (PHARMA MAR SA [ES], et al) [PX] 1,3,4,6,7,10,13,16 * claims 1,5,6 *;
		[X] - BANERJEE D ET AL, "Drug combination studies with Aplidin in experimental leukemia and lymphoma models.", LEUKEMIA, 5TH INTERNATIONAL SYMPOSIUM ON LEUKEMIA AND LYMPHOMA; AMSTERDAM, NETHERLANDS; MARCH 12-15, 2003, (20030306), vol. 17, no. 3, page 686, XP002531925 [X] 1-18 * abstract *
		[X] - "Didemnin B", DRUGS OF THE FUTURE 1992, (1992), vol. 17, no. 1, pages 54 - 55, XP008107010 [X] 1,3,4,6,7,10,13,16 * the whole document *
		[A] - VERA M D ET AL, "Natural products as probes of cell biology: 20 Years of didemnin research", MEDICINAL RESEARCH REVIEWS, (2002), vol. 22, no. 2, pages 102 - 145, XP002531923 [A] 1-18 * pages 121-127 * DOI: http://dx.doi.org/10.1002/MED.10003
		[A] - YAGODA A ET AL, "Cytotoxic chemotherapy for advanced renal cell carcinoma.", THE UROLOGIC CLINICS OF NORTH AMERICA, (1993), vol. 20, no. 2, pages 303 - 321, XP008107009 [A] 1-18 * table 1 *
		[PA] - WHELAN P, "The medical treatment of metastatic renal cell cancer", EAU UPDATE SERIES, (2003), vol. 1, no. 4, pages 237 - 246, XP002531924 [PA] 1-18 * table 1 * DOI: http://dx.doi.org/10.1016/S1570-9124(03)00060-6
		[A] - RAYMOND E ET AL, "PRELIMINARY RESULTS OF A PHASE I AND PHARMACOKINETIC STUDY OF APLIDINE GIVEN AS A 24-HOUR INFUSION EVERY 2 WEEKS IN PATIENTS WITHSOLID TUMORS AND NON HODGKIN'S LYMPHOMAS", PROCEEDINGS OF THE 91ST ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH. SAN FRANCISCO, CA, APRIL 1 - 5, 2000, PROCEEDINGS OF THE ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, PHILADELPHIA, PA : AACR, US, (2000), VOL. 41, page 611, XP001002420 [A] 1-18 * abstract *
		[A] - CHESON B D, "New chemotherapeutic agents for the treatment of low-grade non-Hodgkin's lymphomas", SEMINARS IN ONCOLOGY, (1993), vol. 20, no. SUPPL. 5, pages 96 - 110, XP008107011 [A] 1-18 * the whole document *
		[PX] - BANERJEE DEBABRATA ET AL, "Potential clinical relevance of drug combination studies with aplidine in experimental leukemia and lymphoma models.", PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING, 94TH ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH; WASHINGTON, DC, USA; JULY 11-14, 2003, (200307), vol. 44, page 530, XP001537121 [PX] 1-18 * abstract *
	International search	[X]US6030943 (CRUMB WILLIAM J [US], et al)
	by applicant	WO9109485
		WO9801352
		WO9942125
		WO0176616
		WO0135974
		WO0230441
		WO0202596
		- FAIRCLOTH, G. ET AL., "Preclinical characterization of aplidine, a new marine anticancer depsipeptide", PROC AMER ASSOC CANCER RES, (1997), page 38
		- DEPENBROCK H; PETER R; FAIRCLOTH GT; MANZANARES I; JIMENO J; HANAUSKE AR, "In vitro activity of Aplidine, a new marine-derived anti-cancer compound, on freshly explanted clonogenic human tumour cells and haematopoietic precursor cells", BR. J. CANCER, (1998), vol. 78, pages 739 - 744, XP001002515
		- FAIRCLOTH G; GRANT W; NAM S; JIMENO J; MANZANARES I; RINEHART K., "Schedule-dependency of Aplidine, a marine depsipeptide with antitumor activity", PROC. AM. ASSOC. CANCER RES., (1999), vol. 40, page 394, XP001002421
		- BROGGINI M; MARCHINI S; D'INCALCI M; TARABOLETTI G; GIAVAZZI R; FAIRCLOTH G; JIMENO J., "Aplidine blocks VEGF secretion and VEGF/VEGF-R1 autocrine loop in a human leukemic cell line", CLIN CANCER RES, (2000), vol. 6, page 4509
		- ERBA E; BASSANO L; DI LIBERTI G; MURADORE I; CHIORINO G; UBEZIO P; VIGNATI S; CODEGONI A; DESIDERIO MA; FAIRCLOTH G, "Cell cycle phase perturbations and apoptosis in tumour cells induced by aplidine", BR J CANCER, (2002), vol. 86, pages 1510 - 1517
		- PAZ-ARES L; ANTHONY A; PRONK L; TWELVES C; ALONSO S; CORTES-FUNES H; CELLI N; GOMEZ C; LOPEZ-LAZARO L; GUZMAN C, "Phase I clinical and pharmacokinetic study of aplidine, a new marine didemnin, administered as 24-hour infusion weekly", CLIN. CANCER RES., (2000), vol. 6, page 4509
		- RAYMOND E; ADY-VAGO N; BAUDIN E; RIBRAG V; FAIVRE S; LECOT F; WRIGHT T; LOPEZ LAZARO L; GUZMAN C; JIMENO J, "A phase I and pharmacokinetic study of aplidine given as a 24-hour continuous infusion every other week in patients with solid tumor and lymphoma", CLIN. CANCER RES., (2000), vol. 6, page 4510
		- MAROUN J; BELANGER K; SEYMOUR L; SOULIERES D; CHARPENTIER D; GOEL R; STEWART D; TOMIAK E; JIMENO J; MATTHEWS S, "Phase I study of aplidine in a 5 day bolus q 3 weeks in patients with solid tumors and lymphomas", CLIN. CANCER RES., (2000), vol. 6, page 4509
		- IZQUIERDO MA; BOWMAN A; MARTINEZ M; CICCHELLA B; JIMENO J; GUZMAN C; GERMA J; SMYTH J., "Phase I trial of Aplidine given as a 1 hour intravenous weekly infusion in patients with advanced solid tumors and lymphoma", CLIN. CANCER RES., (2000), vol. 6, page 4509
		- BANERJEE ET AL., LEUKEMIA, (200303), vol. 13, no. 3, page 686
		- BANERJEE ET AL., PROC. AM. ASSOC. FOR CANCER RESEARCH ANNUAL MEETING, (200307), vol. 44, page 530
		- LACERDA J.F. ET AL., BLOOD, (1995), vol. 85, no. 10, pages 2675 - 2679

The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.

Legal notice
Terms of use
24.2.25; 35p